Should Patients on Tamoxifen Be Started on Apixaban (Eliquis)?
No, patients taking tamoxifen should NOT routinely be started on apixaban (Eliquis) solely because they are on tamoxifen. Anticoagulation decisions must be based on specific clinical indications for VTE prophylaxis or treatment, not on tamoxifen use alone.
Clinical Decision Framework
When Apixaban IS Indicated in Tamoxifen Users
Apixaban should be prescribed to patients on tamoxifen only when they meet standard cancer-associated thrombosis criteria:
1. High-Risk Ambulatory Patients Receiving Chemotherapy
- Patients with Khorana score ≥2 who are receiving systemic anticancer therapy may be offered apixaban 2.5 mg twice daily for VTE prophylaxis 1
- This applies regardless of whether they are on tamoxifen or not
- Must have no significant bleeding risk or drug interactions
2. Treatment of Established VTE
- For patients who develop DVT or PE while on tamoxifen, apixaban is an appropriate treatment option (10 mg twice daily for 7 days, then 5 mg twice daily) 1
- Extended prophylaxis after 6 months can use reduced-dose apixaban 2.5 mg twice daily 2
3. Perioperative Prophylaxis
- After major cancer surgery, apixaban 2.5 mg twice daily may be used as an alternative to LMWH for extended prophylaxis (up to 4 weeks), though evidence remains limited 1, 3
When Apixaban Is NOT Indicated
Do not prescribe apixaban for:
- Routine primary prophylaxis in all cancer patients on tamoxifen 1
- Patients hospitalized solely for chemotherapy infusion 1
- Low-risk ambulatory patients (Khorana score <2) without other VTE risk factors
Key Evidence on Tamoxifen-Apixaban Safety
The concern about drug-drug interactions between tamoxifen and DOACs has been addressed: A large population-based cohort study of 4,753 patients found that concurrent use of tamoxifen with DOACs (including apixaban) was not associated with increased hemorrhage risk compared to aromatase inhibitors with DOACs (weighted HR 0.68,95% CI 0.44-1.06) 4. This suggests the theoretical CYP450/P-glycoprotein interaction is not clinically significant for bleeding outcomes.
Important Caveats
Tamoxifen increases VTE risk but this alone does not justify anticoagulation:
- While tamoxifen is a known VTE risk factor, the absolute risk increase does not warrant routine prophylactic anticoagulation in all patients
- Risk stratification using validated tools (Khorana score) is essential 5, 1
Drug interaction considerations:
- Although tamoxifen theoretically interacts with apixaban through CYP450 and P-glycoprotein pathways, real-world evidence shows this is not clinically problematic for bleeding 4
- No dose adjustment of apixaban is needed when co-prescribed with tamoxifen 6
Perioperative management:
- If a patient on both tamoxifen and apixaban requires surgery, discontinue apixaban 24-48 hours before the procedure depending on bleeding risk 6
- Consider temporarily holding tamoxifen perioperatively in high VTE-risk surgeries, though no consensus guidelines exist 7
Bottom Line Algorithm
- Assess VTE indication independently - Does the patient have an established VTE, high Khorana score (≥2), or recent major cancer surgery?
- If YES → Apixaban is appropriate per standard cancer-associated thrombosis guidelines
- If NO → Do not prescribe apixaban; tamoxifen use alone is not an indication
- Safety check - Concurrent tamoxifen-apixaban use is safe based on current evidence 4